The risk of cancer in people with diabetes and chronic kidney disease

Germaine Wong; Sophia Zoungas; Serigne Lo; John Chalmers; Alan Cass; Bruce Neal; Mark Woodward; Vlado Perkovic; Paul Glasziou; Bryan Williams; Kirsten Howard; Jeremy Chapman; Jonathan Craig

doi:10.1093/ndt/gfs022

The risk of cancer in people with diabetes and chronic kidney disease

Germaine Wong, Sophia Zoungas, Serigne Lo, John Chalmers, Alan Cass, Bruce Neal, Mark Woodward, Vlado Perkovic, Paul Glasziou, Bryan Williams, Kirsten Howard, Jeremy Chapman, Jonathan Craig

Wellbeing and Preventable Chronic Disease

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes.

Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial.

Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4%) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95% confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD.

Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).

Original language	English
Pages (from-to)	3337-3344
Number of pages	8
Journal	Nephrology Dialysis Transplantation
Volume	27
Issue number	8
DOIs	https://doi.org/10.1093/ndt/gfs022
Publication status	Published - 2012

Access to Document

10.1093/ndt/gfs022

Cite this

@article{4bed0854d453450f82b19205fd458737,

title = "The risk of cancer in people with diabetes and chronic kidney disease",

abstract = "Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes. Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4%) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95% confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD. Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).",

author = "Germaine Wong and Sophia Zoungas and Serigne Lo and John Chalmers and Alan Cass and Bruce Neal and Mark Woodward and Vlado Perkovic and Paul Glasziou and Bryan Williams and Kirsten Howard and Jeremy Chapman and Jonathan Craig",

year = "2012",

doi = "10.1093/ndt/gfs022",

language = "English",

volume = "27",

pages = "3337--3344",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - The risk of cancer in people with diabetes and chronic kidney disease

AU - Wong, Germaine

AU - Zoungas, Sophia

AU - Lo, Serigne

AU - Chalmers, John

AU - Cass, Alan

AU - Neal, Bruce

AU - Woodward, Mark

AU - Perkovic, Vlado

AU - Glasziou, Paul

AU - Williams, Bryan

AU - Howard, Kirsten

AU - Chapman, Jeremy

AU - Craig, Jonathan

PY - 2012

Y1 - 2012

N2 - Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes. Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4%) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95% confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD. Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).

AB - Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes. Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4%) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95% confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD. Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).

U2 - 10.1093/ndt/gfs022

DO - 10.1093/ndt/gfs022

M3 - Article

SN - 0931-0509

VL - 27

SP - 3337

EP - 3344

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 8

ER -

The risk of cancer in people with diabetes and chronic kidney disease

Abstract

Access to Document

Fingerprint

Cite this